|
|
|
| Dec. 15, 2004 |
FDA Approves Kepivance for Severe Oral Mucositis in Cancer Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study Published in This Week's New England Journal of Medicine
|
| Dec. 14, 2004 |
Amgen Names Willard Dere Senior Vice President, Global Development
|
| Dec. 11, 2004 |
Randomized Head-to-Head Trial Shows Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week in Breast Cancer Patients
|
| Dec. 10, 2004 |
Phase 3 Study Shows Majority of Neutropenia with Related Fever and Hospitalization Occurs in First Treatment Cycle for Breast Cancer Patients Not Receiving Neulasta
|
| Dec. 6, 2004 |
FDA Grants Fast Track Designation for Amgen's AMG 531 and AMG 706 Experimental Therapies to Potentially Treat Life-Threatening Conditions
|
| Nov. 29, 2004 |
Nominations Open for the Amgen Award For Science Teaching Excellence; 19 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates
|
| Nov. 29, 2004 |
Nominations Open for the Amgen Award For Science Teaching Excellence
|
| Nov. 24, 2004 |
Published Head-to-Head Data Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once-a-Week
|
| Nov. 15, 2004 |
Amgen Announces Offer of $2 Billion in Two Series of Senior Notes
|
| Nov. 11, 2004 |
Amgen Announces the Formation of Amgen Ventures; Venture Capital Fund Designed to Provide Resources to Help Advance Early-Stage Biotechnology Companies and Human Therapeutics
|
| Nov. 1, 2004 |
Amgen Launches Landmark Trial to Evaluate the Impact of Treating Anemia on Cardiovascular Risks in Patients with Chronic Kidney Disease and Type 2 Diabetes
|
| Nov. 1, 2004 |
Interim Phase 2 Data Suggest Activity of Panitumumab with Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
|
| Oct. 28, 2004 |
European Commission Approves Innovative First-in-Class Treatment for a Serious Complication of Chronic Kidney Disease
|
| Oct. 20, 2004 |
Amgen's Third Quarter 2004 Adjusted Earnings Per Share Increased 21 Percent to 64 Cents
|
| Oct. 18, 2004 |
New Two-Year Data Show That Most Rheumatoid Arthritis Patients Treated with ENBREL Plus Methotrexate Had No Progression of Joint Damage
|
| Oct. 15, 2004 |
Court Rules in Amgen's Favor in TKT Litigation; Affirms Validity of EPO Patents
|
| Oct. 13, 2004 |
Amgen Names Rolf Hoffmann Senior Vice President, European Operations
|
| Oct. 3, 2004 |
Amgen Investigational Therapy for Bone Loss, AMG 162, Increased Bone Mineral Density with Twice Yearly Injection
|
| Sep. 28, 2004 |
FDA Approves ENBREL to Induce Major Clinical Response in Patients With Rheumatoid Arthritis; Additional Data Demonstrates Increased Levels of Sustained Disease Control
|
| Sep. 28, 2004 |
FDA Approves New and Easy Way to Take ENBREL; Benefits of ENBREL Delivered in Convenient Once-Weekly 50 mg/mL Prefilled Syringe
|
| Sep. 21, 2004 |
Aranesp Approved for Extended Dosing by European Commission
|
| Sep. 16, 2004 |
Amgen Names Arvind Sood Vice President, Investor Relations
|
| Aug. 13, 2004 |
Amgen Completes Acquisition of Tularik; Acquisition Enhances Amgen's Strong Research Organization and Establishes Amgen in the San Francisco Bay Area
|
| Aug. 10, 2004 |
First Patients Dosed with Amgen's AMG 162 In Phase 3 Studies for Postmenopausal Osteoporosis and Treatment-Induced Bone Loss
|
| Aug. 6, 2004 |
Aranesp Receives Positive Regulatory Opinion for Extended Dosing in Europe
|
| Jul. 30, 2004 |
Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion for Approval in Europe
|
| Jul. 26, 2004 |
Lifestyle Coaching Program Launched Today Helps People with Rheumatoid Arthritis Remain Active
|
| Jul. 22, 2004 |
Amgen's Second Quarter 2004 Total Product Sales, Adjusted Earnings and GAAP Earnings Per Share Increased 27 Percent
|
| Jul. 12, 2004 |
Amgen Names Brian Kotzin Vice President, Inflammation Clinical Development and Willard Dere Vice President, General Medicine
|
| Jul. 1, 2004 |
Amgen Names Joshua Ofman Vice President, Reimbursement and Payment Policy
|
| Jun. 28, 2004 |
Amgen's Phase 2 Study of GDNF for Advanced Parkinson's Disease Fails to Meet Primary Endpoint; Six Months of Treatment Showed Biological Effect But No Clinical Improvement
|
| Jun. 24, 2004 |
Phase 3 Study Shows First-Cycle Administration of Neulasta Significantly Lowers Incidence of Infection and Hospitalization
|
| Jun. 24, 2004 |
Amgen Submits Biologics License Application for FDA Approval of Palifermin
|
| Jun. 10, 2004 |
New Two-Year Data Demonstrate That ENBREL Therapy Allowed Significantly More Rheumatoid Arthritis Patients to Achieve Clinical Remission
|
| Jun. 8, 2004 |
Study Results Demonstrate Aranesp Dosed Once Every Three Weeks Achieves Treatment Goals in Managing Anemia in Cancer Patients Receiving Chemotherapy
|
| Jun. 8, 2004 |
Head-to-Head Studies Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week
|
| Jun. 6, 2004 |
Study Results Demonstrate the Activity of Aranesp in Treating Anemia in Cancer Patients Not Receiving Chemotherapy
|
| Jun. 6, 2004 |
Interim Phase 2 Data Show Panitumumab Has Single-Agent Antitumor Activity in Metastatic Colorectal Cancer; Response Appears Independent of Prior Chemotherapy Regimen
|
| May. 20, 2004 |
Catwalk Beauty Vendela To Help Educate Public About Effects of Psoriasis Through ``Making Connections'' Health Education Campaign
|
| Apr. 30, 2004 |
FDA Approves ENBREL to Treat Psoriasis; New Convenient Treatment Provides Rapid and Significant Relief of Symptoms
|
| Apr. 28, 2004 |
2004 Cambridge-Boston Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 28, 2004 |
2004 Rhode Island Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 22, 2004 |
Amgen's First Quarter 2004 Adjusted Earnings Per Share Increased 36 Percent to 57 Cents
|
| Apr. 20, 2004 |
2004 Puerto Rico Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 19, 2004 |
2004 Washington Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 19, 2004 |
2004 Colorado Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 19, 2004 |
2004 Kentucky Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 19, 2004 |
2004 California Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 8, 2004 |
Immunomedics Regains North American Development Rights from Amgen for Epratuzumab
|
| Apr. 8, 2004 |
Sensipar Pivotal Studies in over 700 Patients Published in New England Journal of Medicine
|
| Mar. 30, 2004 |
Amgen Names Rodger Currie Vice President, Government Affairs
|
| Mar. 29, 2004 |
Amgen to Acquire Tularik for $1.3 Billion
|
| Mar. 23, 2004 |
Amgen's First Research and Development Day Highlighted 24 of the Approximately 40 Programs in its Pipeline
|
| Mar. 10, 2004 |
Frank Herringer Nominated for Amgen Board of Directors
|
| Mar. 9, 2004 |
Leonard Schaeffer Joins Amgen's Board of Directors
|
| Mar. 8, 2004 |
FDA Approves Innovative, First-In-Class Treatment for a Serious Complication of Chronic Kidney Disease
|
| Feb. 25, 2004 |
Amgen Opens State-of-the-Art Biotechnology Research Campus
|
| Feb. 23, 2004 |
Amgen Announces Webcast of R&D Day With the Investment Community
|
| Feb. 7, 2004 |
New Phase 3 ENBREL Data Show Psoriasis Patients Achieved a Therapeutic Response From 'Step Down' Dosing Regimen
|
| Jan. 22, 2004 |
Amgen's Fourth Quarter 2003 Adjusted Earnings Per Share Increased 31 Percent to 46 Cents; Full Year 2003 Adjusted Earnings Per Share Increased 37 Percent to $1.90
|
| Jan. 14, 2004 |
Amgen Announces Webcast of Fourth Quarter and Full Year 2003 Financial Results
|
| Jan. 13, 2004 |
Amgen Names David J. Scott Senior Vice President, General Counsel and Secretary
|
| Jan. 5, 2004 |
Amgen Announces Award for Science Teaching Excellence in Rhode Island
|
| Jan. 5, 2004 |
Amgen Announces Award for Science Teaching Excellence in Colorado
|
| Jan. 5, 2004 |
Amgen Announces Award for Science Teaching Excellence in California
|
| Jan. 5, 2004 |
Amgen Announces Award for Science Teaching Excellence
|
| Jan. 5, 2004 |
Amgen Announces Award for Science Teaching Excellence in Puerto Rico
|
|
|
|
|
|
|
|
|
|
|
|
